Wall Street analysts expect Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) to post earnings of ($0.10) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Brainstorm Cell Therapeutics’ earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.03). Brainstorm Cell Therapeutics posted earnings of $0.02 per share during the same quarter last year, which suggests a negative year over year growth rate of 600%. The firm is scheduled to announce its next earnings results on Thursday, March 14th.
According to Zacks, analysts expect that Brainstorm Cell Therapeutics will report full-year earnings of ($0.53) per share for the current fiscal year, with EPS estimates ranging from ($0.61) to ($0.47). For the next fiscal year, analysts expect that the company will post earnings of ($0.30) per share, with EPS estimates ranging from ($0.69) to ($0.10). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Brainstorm Cell Therapeutics.
Several brokerages recently commented on BCLI. Maxim Group reissued a “buy” rating and set a $9.00 price target on shares of Brainstorm Cell Therapeutics in a research report on Tuesday, January 22nd. Dawson James reissued a “buy” rating on shares of Brainstorm Cell Therapeutics in a research report on Tuesday, December 18th.
An institutional investor recently raised its position in Brainstorm Cell Therapeutics stock. ETF Managers Group LLC grew its holdings in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) by 75.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 66,797 shares of the biotechnology company’s stock after buying an additional 28,809 shares during the period. ETF Managers Group LLC owned 0.32% of Brainstorm Cell Therapeutics worth $237,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.82% of the company’s stock.
Shares of NASDAQ BCLI opened at $4.05 on Friday. Brainstorm Cell Therapeutics has a 52 week low of $2.92 and a 52 week high of $5.35. The company has a market cap of $83.86 million, a P/E ratio of -15.58 and a beta of 1.33.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Further Reading: Do back-end load funds outperform no-load funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.